Click Therapeutics Secures $48.6M Series A Funding to Accelerate the Future of Digital Therapeutics

Click Therapeutics, Inc. is proud to announce that it has successfully raised $48,600,000 in its latest funding round, marking a significant milestone in the journey to transform healthcare through digital therapeutics. As a pioneering leader in developing, validating, and commercializing software as prescription medical treatments, our company is dedicated to addressing the needs of patients who have long been underserved by traditional pharmaceuticals. This substantial capital injection will be strategically directed toward expanding our innovative pipeline of FDA-regulated digital treatments, refining our shared platform technologies, and accelerating the integration of novel cognitive, behavioral, and neuromodulatory mechanisms into our programs. By leveraging advanced data-driven tools—including artificial intelligence and machine learning—Click Therapeutics is uniquely positioned to deliver engaging, clinically proven interventions across diverse therapeutic areas such as psychiatry, neurology, oncology, cardiology, and immunology. Our approach focuses on combining technical and scientific rigor with patient-centric design, ensuring that each solution not only meets stringent regulatory standards but also delivers compelling clinical outcomes. This milestone underscores our commitment to accessibility by bringing safe, effective, and personalized prescription digital therapeutics directly to patients via their smartphones. As we celebrate this achievement, we remain dedicated to fostering an inclusive, diverse, and innovative workplace where clinicians, scientists, and technologists collaborate to redefine the future of medicine. The funds will empower us to further our mission of revolutionizing treatment paradigms and addressing unmet medical needs, ultimately advancing patient care both domestically and around the world.